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Proper O-mannosyl glycosylation is required for central 
nervous system (CNS) development and function, and it is 
known that O-mannose-initiated glycans comprise a large 
portion of the total O-glycans in the mammalian brain [1]. 
Mutations in genes involved in O-mannosylation give rise to 
congenital muscular dystrophies with associated CNS abnor-
malities [2-5]. A deficient glycosylation of dystroglycan (DG), 
which thus far is the best characterized O-mannosylated 
protein, accounts for the muscular and neurologic phenotypes 
associated with dystroglycanopathies [2,3,6,7]. This group of 
recessively inherited disorders is clinically characterized by 
various combinations of severe muscular dystrophy, mental 
retardation, and ocular abnormalities [2,3,5]. Thus far, 
mutations in 18 genes have been identified in patients with 
dystroglycanopathies, most of which code for glycosyltrans-
ferases, DG itself, or proteins of unknown function in DG 
glycosylation [8,9].
DG is a glycoprotein that constitutes the central compo-
nent of the dystrophin-glycoprotein complex. This transmem-
brane multimeric complex is made up of dystrophin, sarco-
glycan, sarcospan, and syntrophin, among other proteins, 
being responsible for the linkage of the cytoskeleton of muscle 
and nerve cells to the extracellular matrix [4,9,10]. These 
proteins play an important role in maintaining muscle integ-
rity and are involved in proper CNS development, structure, 
Molecular Vision 2016; 22:658-673 <http://www.molvis.org/molvis/v22/658>
Received 3 October 2015 | Accepted 14 June 2016 | Published 16 June 2016
© 2016 Molecular Vision
658
Expression pattern in retinal photoreceptors of POMGnT1, a 
protein involved in muscle-eye-brain disease
Mary Luz Uribe,1,2 Carmen Haro,1 María Paz Ventero,1 Laura Campello,1 Jesús Cruces,2,3 José Martín-
Nieto1,2,4
1Departamento de Fisiología, Genética y Microbiología, Facultad de Ciencias, Universidad de Alicante, Alicante, Spain; 
2Instituto de Investigación Sanitaria del Hospital Universitario La Paz (IdiPAZ), Madrid, Spain; 3Departamento de Bioquímica, 
Instituto de Investigaciones Biomédicas ‘Alberto Sols’ UAM-CSIC, Facultad de Medicina, Universidad Autónoma de Madrid, 
Madrid, Spain; 4Instituto Multidisciplinar para el Estudio del Medio (IMEM) 'Ramón Margalef', Universidad de Alicante, 
Alicante, Spain
Purpose: The POMGNT1 gene, encoding protein O-linked-mannose β-1,2-N-acetylglucosaminyltransferase 1, is associ-
ated with muscle-eye-brain disease (MEB) and other dystroglycanopathies. This gene’s lack of function or expression 
causes hypoglycosylation of α-dystroglycan (α-DG) in the muscle and the central nervous system, including the brain 
and the retina. The ocular symptoms of patients with MEB include retinal degeneration and detachment, glaucoma, and 
abnormal electroretinogram. Nevertheless, the POMGnT1 expression pattern in the healthy mammalian retina has not 
yet been investigated. In this work, we address the expression of the POMGNT1 gene in the healthy retina of a variety 
of mammals and characterize the distribution pattern of this gene in the adult mouse retina and the 661W photoreceptor 
cell line.
Methods: Using reverse transcription (RT)–PCR and immunoblotting, we studied POMGNT1 expression at the mRNA 
and protein levels in various mammalian species, from rodents to humans. Immunofluorescence confocal microscopy 
analyses were performed to characterize the distribution profile of its protein product in mouse retinal sections and in 
661W cultured cells. The intranuclear distribution of POMT1 and POMT2, the two enzymes preceding POMGnT1 in 
the α-DG O-mannosyl glycosylation pathway, was also analyzed.
Results: POMGNT1 mRNA and its encoded protein were expressed in the neural retina of all mammals studied. 
POMGnT1 was located in the cytoplasmic fraction in the mouse retina and concentrated in the myoid portion of the 
photoreceptor inner segments, where the protein colocalized with GM130, a Golgi complex marker. The presence of 
POMGnT1 in the Golgi complex was also evident in 661W cells. However, and in contrast to retinal tissue, POMGnT1 
additionally accumulated in the nucleus of the 661W photoreceptors. Colocalization was found within this organelle 
between POMGnT1 and POMT1/2, the latter associated with euchromatic regions of the nucleus.
Conclusions: Our results indicate that POMGnT1 participates not only in the synthesis of O-mannosyl glycans added 
to α-DG in the Golgi complex but also in the glycosylation of other yet-to-be-identified proteins in the nucleus of mouse 
photoreceptors.
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and function, myelination and architecture of peripheral 
nerves, epithelial morphogenesis, cell adhesion, and signal 
transduction, among other functions [10,11]. DG is trans-
lated from the DAG1 gene (Gene ID 1605, OMIM 128239) 
as a precursor polypeptide, which through posttranslational, 
proteolytic cleavage is excised into two subunits, α-DG and 
β-DG. The first is extracellularly located and heavily glyco-
sylated, and the second is a transmembrane polypeptide. 
α-DG glycosylation is essential for its proper functioning 
[5,9,10], as the attached O-mannosyl glycans confer α-DG 
the ability to bind to its protein ligands in the extracellular 
matrix of muscle and CNS tissues and to synaptic molecules, 
including laminin, perlecan, agrin, neurexin, pikachurin, 
and slit [9,11,12]. Among these molecules, pikachurin is 
exclusively expressed in the retina and mediates the proper 
synaptic connection between retinal photoreceptors and 
bipolar cells [13].
Mutations in POMGNT1, the first described dystrogly-
canopathy-associated gene [14], have been mainly associated 
with the development of muscle-eye-brain disease (MEB) 
[15-17], a severe neuromuscular dystrophy, although they 
have also been described in patients with Walker-Warburg 
syndrome (WWS) [18], both collected in the OMIM data-
base under entry MDDGA3 (OMIM 253280), as well as with 
moderate congenital muscular dystrophy with mental retarda-
tion, type B3 (MDDGB3, OMIM 613151) [15,16], and with the 
milder limb-girdle muscular dystrophy (LMGD) with no CNS 
affectation, type 2O (MDDGC3, OMIM 613157) [19]. This 
gene encodes the enzyme dubbed protein O-linked-mannose 
β-1,2-N-acetylglucosaminyltransferase 1 (POMGnT1), 
contains 22 exons, and is located in chromosome region 
1p34.1 (OMIM 606822). Transcription of the POMGNT1 gene 
gives rise to a 2.7 kb mRNA in different tissues, with higher 
expression levels in the skeletal muscle, heart, and kidney and 
lower levels in the brain [14]. POMGnT1 (EC 2.4.1.101) is a 
protein belonging to the GT13 family of glycosyltransferases 
according to the Carbohydrate-Active enZYmes (CAZy) 
database [20]. In humans, the main isoform of POMGnT1 
contains 660 amino acids whose sequence yields a calcu-
lated molecular mass of 75,252 Da (UniProtKB Q8WZA1). 
We have recently described the case of a patient with an 
MDDGC3 variant in which the causative mutation was not 
found in the POMGNT1 coding sequence but in its promoter 
region [21]. This mutation causes underexpression of this 
gene at the mRNA level, leading to hypoglycosylation of 
α-DG and the development of MEB symptoms.
In addition to POMGnT1, enzyme activity has been 
demonstrated for other glycosyltransferases involved in 
dystroglycanopathies, such as protein O-mannosyltransferases 
POMT1 and POMT2 (EC 2.4.1.109). These are thought 
to form a heterodimer active in the addition of mannose 
to serine or threonine residues of α-DG [22,23], which 
are numerous and located in its mucin-like domain [9,10]. 
POMGnT1 then functions to catalyze the second step in 
the synthesis of α-DG O-mannosyl glycans (cores M1 and 
M2) by covalently attaching, with a β1–2 linkage, one unit 
of N-acetylglucosamine to the previously added O-mannose 
residue [11,14,24]. Thus far, POMGnT1 has been localized 
to the Golgi complex when exogenously expressed in a 
few established cell lines [25,26], and the protein has been 
recently shown to be associated with a Golgi-resident protein 
known as Golgi phosphoprotein 3 (GOLPH3) [27].
To investigate the in vivo function of POMGnT1, MEB 
mouse models have been generated through Pomgnt1 gene 
inactivation that exhibit multiple defects in the muscle, brain, 
and eye, comparable to those experienced by people affected 
by MEB [28-30]. To date, the distribution of POMGnT1 in 
the vertebrate retina has not been studied, and the protein’s 
pattern of expression and intracellular localization have not 
been determined in any mammalian tissue. In this work, we 
analyzed the expression of POMGNT1 mRNA and protein in 
the retina of various mammalian species. We also focused on 
characterizing the distribution pattern in the neural retina of 
POMGnT1 in healthy adult mice and in the established cell 
line of cone photoreceptors, 661W. Interestingly, in addition 
to being found in the Golgi complex, POMGnT1 was found to 
concentrate in the nucleus of 661W cells. This led us to jointly 
assess the possible intranuclear presence of its preceding 
enzymes in α-DG O-glycosylation, POMT1 and POMT2, in 
this photoreceptor cell line.
METHODS
Animals: The following mammalian species studied in this 
work were all adults: mouse (Mus musculus, C57BL/6J), rat 
(Rattus norvegicus, Sprague-Dawley), cow (Bos taurus), 
cynomolgus monkey (Macaca fascicularis), and human 
(Homo sapiens). All animal handling was performed in 
compliance with the rules set by the National Institutes of 
Health (USA), the ARVO Statement for the Use of Animals 
in Ophthalmic and Vision Research, and the European 
Directive 2010/63/EU. Rodents were held at the Universidad 
de Alicante animal-care facility and euthanized upon CO2 
inhalation followed by cervical dislocation. Their eyes were 
enucleated and stored in RNAlater solution (Ambion; Austin, 
TX). Bovine eyes were freshly obtained from the Alicante 
municipal slaughterhouse. Monkeys were kept as described 
[31] at the animal care facility of the Universidad de Murcia 
(Spain), and their eyes were kindly donated by Dr. M.T. 
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Herrero. All protocols and primate handling procedures 
used were approved by the university bioethics research 
committee. Young adult monkeys were anesthetized with 
ketamine (10 mg/kg, i.m.) and then administered a lethal 
injection of pentobarbital (50 mg/kg, i.p.), and the eyeballs 
were immediately enucleated following sacrifice. All animal 
eyes were kept at –80 °C until the retinas were dissected for 
RNA or protein isolation. For immunohistochemistry, mouse 
eyes were fixed in 4% paraformaldehyde in 0.1 M sodium 
phosphate buffer pH 7.4 (PB) for 1 h and then subjected to 
sucrose cryoprotection [32].
Cell culture: The 661W photoreceptor cell line was kindly 
provided by Dr. M. Al-Ubaidi (University of Oklahoma). It 
was cloned from a retinal tumor of a transgenic mouse line 
that expressed the artificial HIT1 transgene (SV40 large T 
antigen under control of the human inter-photoreceptor 
retinol-binding protein (IRBP) gene (Gene ID 5949, OMIM 
180290) promoter) [33]. These immortalized cells express 
cone molecular markers, such as opsins, transducin, and cone 
arrestin, and lack proteins specific to rods or other retinal 
cell types, constituting a light-sensitive, homogeneous cell 
line [34,35]. The 661W cells were authenticated with short 
tandem repeats (STR) genotyping (IDEXX BioResearch, 
Ludwigsburg, Germany), and the genetic profile was verified 
to be consistent with a mixed FVB × C57BL/6 mouse strain 
of origin, as expected, and to carry the HIT1 transgene, which 
makes this cell line unique (Appendix 1) [33]. The cells were 
grown on Dulbecco’s modified Eagle medium (DMEM) from 
HyClone (Logan, UT), supplemented with 10% fetal bovine 
serum from Gibco (Grand Island, NY), 2 mM L-glutamine, 
and 1% penicillin/streptomycin (HyClone), at 37 °C in a 
humidified atmosphere containing 5% CO2. Cells were 
expanded on 75 cm2 flasks, and after five to ten passages 
under culture conditions, the cells were frozen at –80 °C until 
RNA or protein extraction was performed, or else they were 
seeded on 24-well culture plates and used for immunocyto-
chemistry when they were nearly confluent.
Reverse transcription–PCR: The neural retina was dissected 
out, free from the retinal pigment epithelium (RPE), from 
eyes stored in RNAlater. Total RNA was extracted from 
the retinal tissue and 661W cells using the TRIzol reagent 
(Invitrogen; Carlsbad, CA) and then treated with DNase 
I using the TURBO DNA-free kit (Ambion). RNA from 
human retinas (29 donors, 20–60 years at death) was 
purchased from Clontech BD (Mountain View, CA). Reverse 
transcription into cDNA was performed using the RETRO-
script kit (Ambion), and subsequent PCR amplification was 
performed essentially as described [36,37]. Primers for genes 
POMGNT1, POMT1, and POMT2 (Table 1) were designed 
using the Primer3 software [38] to bear a Tm of 60 °C and 
flank at least one intron of the corresponding gene. PCR reac-
tions (40 μl) contained 20 ng of cDNA, forward and reverse 
primers at 0.4 μM each, the four deoxynucleotides (dNTPs) at 
0.2 mM each, and 1 U of GoTaq DNA polymerase (Promega; 
Madison, WI). After an initial denaturation step at 94 °C for 
2 min, amplification was performed for a total of 35 cycles 
each at 94 °C for 30 s, 60 °C for 20 s, and 72 °C for 30 s, and 
concluded with a final elongation step at 72 °C for 5 min. 
PCR products were run on 2% agarose gels with added SYBR 
Green I (Sigma-Aldrich; St. Louis, MO) and photographed 
under ultraviolet (UV) light.
Immunoblotting: Total proteins were extracted from the 
neural retinas and 661W cells as previously described [36]. 
Briefly, 20 μl of lysis buffer supplemented with protease 
inhibitors was added per 5 mg of tissue or 106 cells, and after 
incubation on ice for 15–20 min, the supernatant obtained 
upon centrifugation at 16,000 ×g at 4 °C for 10 min consti-
tuted the total protein fraction. To obtain the cytoplasmic 
and nuclear protein fractions, the NE-PER kit from Pierce 
(Rockford, IL) was used. Samples (20 mg of retina or 2×106 
cells) were homogenized in 200 μl of CER I lysis buffer 
supplemented with protease inhibitors and kept on ice for 10 
min. Then 11 μl of CER II lysis buffer was added, and after 
centrifugation as above for 5 min, the supernatant obtained 
constituted the cytoplasmic fraction. To the pellet, a volume 
of 100 μl of cold NER lysis buffer was added, and after 
incubation on ice for 40 min, the supernatant obtained after 
centrifugation as above for 10 min constituted the nuclear 
fraction.
Proteins (100 μg/lane) were resolved with sodium 
dodecyl sulfate–polyacrylamide gel electrophoresis 
(SDS–PAGE) on 5–20% polyacrylamide-gradient gels and, 
after electrotransfer to polyvinylidene f luoride (PVDF) 
membranes (GE Healthcare, Buckinghamshire, UK), stained 
with SYPRO Ruby Protein Blot Stain (Molecular Probes; 
Eugene, OR) to ensure even protein loading and transfer. 
Immunodetection was performed essentially as described 
[31,36,37]. The membranes were probed sequentially with 
primary antibodies (Table 2) at 4 °C overnight and with 
horseradish peroxidase-conjugated anti-immunoglobulin 
(anti-IgG) secondary antibodies at a 1:10,000 dilution for 1 h. 
Development was performed with enhanced chemilumines-
cence using the SuperSignal kit from Pierce, upon exposure 
of the X-ray films (GE Healthcare) to immunoblots. Absence 
of cross contamination between the cytoplasmic and nuclear 
fractions was assessed with immunoblotting using antibodies 
to proteins exclusively found in these compartments, namely, 
β-tubulin III and lamin A/C, respectively (Table 2).
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Table 1. Primers used for rT–PCr in This work.
Gene Species Primer Sequences Exon PCR product size (bp)
POMGNT1 Hu, Mk, Rt, Mo Fw: 5‘-ATCCTACCACTTTGGCATCG-3′ 17 108
  Rv: 5‘-ACATTCCTGAGCTGGACACC-3′ 18  
 Bv Fw: 5‘-ATCCTACCACTTCGGCATCG-3′ 17 108
  Rv: 5‘-ACATTCCTGAGCTGGACACC-3′ 18  
POMT1 Hu, Mk Fw: 5‘-AATCATGTCCAGTGCCTTCC-3′ 9 165
  Rv: 5‘-ATCATGGGGTAGGTGTCCTG-3′ 10  
 Bv Fw: 5‘-AATCATGTCCAGTGCCTTCC-3′ 9 165
  Rv: 5‘-ATCATAGGGTAGGTGCTCTGGT-3′ 10  
 Rt, Mo Fw: 5‘-AATCATGTCCAGTGCCTTCC-3′ 9 165
  Rv: 5‘-ATCATGGGATAGGTGTTCTTGT-3′ 10  
POMT2 Hu, Mk Fw: 5‘-GGTTTGGTGGCTGAATCTGT-3′ 18 222
  Rv: 5‘-ATGGCTGGGAAGTAGTGGTG-3′ 19  
 Bv Fw: 5‘-TCCTGTGCCTCATAGTGCTG-3′ 7 238
  Rv: 5‘-TAGAAGTGCCTGTGCGAGTG-3′ 9  
 Rt Fw: 5‘-TCCTGTGCCTCATAGTGCTG-3′ 7 176
  Rv: 5‘-AGAGCCATACGCCAAGTGTT-3′ 8-9  
 Mo Fw: 5‘-GTCTGGTGGCTGAATCTGGT-3′ 18 221
  Rv: 5‘-ATGGCTGGGAAGTAGTGGTG-3′ 19  
The sequences of forward (Fw) and reverse (Rv) primers used in this work are indicated. The exon to which each primer aligns is indi-
cated in the penultimate column. The PCR product size is indicated in the last column for each primer pair. Hu: human, Mk: monkey, Bv: 
bovine, Rt: rat, Mo: mouse. For the 661W cell line the mouse primers were used.
Table 2. Primary anTibodies used in This work.
Protein Antibody Company Catalog no.
Working dilution  
IB IHC ICC
POMGnT1 Mouse, 6C12 Sigma-Aldrich WH0055624M7 1:250 1:100 1:250
POMT1 Rabbit, polyclonal Sigma-Aldrich SAB2101845 1:1000 – –
POMT1 Rabbit, polyclonal Eurogenteca SP26a – – 1:50
POMT2 Rabbit, polyclonal Sigma-Aldrich HPA003663 1:250 – –
POMT2 Goat, polyclonal Santa Cruzb sc-48919 – – 1:50
β-tubulin III Rabbit, polyclonal Sigma-Aldrich T3952 1:1,000 – –
Lamin A/C Mouse, 4C11 Sigma-Aldrich SAB200236 1:10,000 – –
GM130 Goat, polyclonal Santa Cruz sc-16271 – 1:100 –
GM130 Rabbit, EP892Y Abcamc ab52649 – – 1:250
Cone arrestin Rabbit, polyclonal Millipored AB15282 – 1:500 –
H3K4me3 Rabbit, polyclonal Abcam ab8580 – – 1:100
HP1α Goat, polyclonal Abcam ab77256 – – 1:250
The two first columns list the antigen and animal origin of the antibody. The clone code is specified for monoclonal antibodies. The two 
central columns indicate the commercial company and antibody catalog reference. The three last columns specify the dilution at which 
each antibody was used on immunoblotting (IB), immunocytochemistry (ICC) or immunohistochemistry (IHC). aEurogentec (Liège, 
Belgium), bSanta Cruz Biotechnology (Santa Cruz, CA), cAbcam (Cambridge, MA), dMerck Millipore (Darmstad, Germany).
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Immunohistochemistry: Cryostat vertical sections (14–16 μm 
thick) were obtained and processed for immunohistochem-
istry essentially as described [32,36,37]. Sections were 
subjected to single or double immunostaining with primary 
antibodies (Table 2) in phosphate buffer (PB) supplemented 
with 1% (v/v) Triton X-100 (PBX) at room temperature over-
night. Thereafter, the samples were incubated in the presence 
of secondary antibodies to IgG developed in donkey and 
conjugated to Alexa Fluor 488 (green) or 546 (red; Molecular 
Probes), at a 1:100 dilution in PBX. 4’,6-Diamidino-2-phe-
nylindole (DAPI) was simultaneously added at 10 μg/ml, and 
incubation took place for 1 h at room temperature with gentle 
shaking in the dark in a humidified chamber. Control samples 
in which primary antibodies were omitted and the corre-
sponding secondary antibodies were included were processed 
in parallel. Fluorescence was detected with a Leica TCS SP2 
confocal laser scanning microscope (Leica Microsystems; 
Wetzlar, Germany). Colocalization was assessed with the 
JACoP plugin developed for the NIH ImageJ software. A 
Pearson’s coefficient (PC) close to 1 was taken as indicative 
of complete colocalization and close to 0 of no colocalization 
[39]. Each PC value was calculated as the average ± standard 
deviation (SD) from five cryosections, each belonging to a 
separate experiment, in which the inner segment (IS) layer 
was cropped before analysis.
Immunocytochemistry: The 661W photoreceptors were 
seeded on 24-well culture plates at 75,000 cells per well and 
grown on a 5% CO2 atmosphere at 37 °C for 24 h. Then the 
cells were fixed with 4% paraformaldehyde in Dulbecco’s 
PBS (DPBS) for 10 min. Thereafter, they were permeabilized 
in situ with 0.2% Triton X-100 in DPBS for 10 min, and then 
non-specific binding was prevented by incubation with 1% 
bovine serum albumin (BSA) in DPBS (blocking solution) 
for 1 h. Subsequently, the cells were incubated with primary 
antibodies at the dilutions indicated in Table 2 in blocking 
solution in a humidified chamber at 4 °C overnight. The SP26 
antibody to POMT1 was custom-made against amino acids 
510-524 of the human protein [40]. Thereafter, they were 
incubated with secondary antibodies to IgG at a 1:100 dilution 
and 10 μg/ml DAPI at room temperature for 2 h. Controls, 
fluorescence detection with confocal microscopy, and colo-
calization analyses were performed as indicated above. Each 
PC value was calculated as the average ± SD of ten cells from 
three micrographs, each obtained in a separate experiment. 
The 661W nuclei or Golgi complexes, as indicated in each 
case, were cropped before analysis.
RESULTS
To assess whether the gene encoding POMGnT1 is expressed 
in the mammalian retina, eyes from different species were 
enucleated, and the neural retina was dissected out for total 
RNA and protein isolation. With RT–PCR using primers 
specific for each mammal, we found that the POMGNT1 
gene was transcribed in the retina of all species, from rodents 
(mouse and rat) and bovine to primates (monkey and human; 
Figure 1A). Expression of this gene was also detected in 
the mouse cell line of cone photoreceptors, 661W. Next, we 
assessed with immunoblotting whether the protein product, 
POMGnT1, was synthesized in the retina and found coherent 
results with mRNA expression. As shown in Figure 1B, the 
POMGnT1 enzyme was detected in the retina of all mamma-
lian species analyzed, as well as in the 661W photoreceptors, 
migrating with an apparent molecular mass of 75 kDa as 
expected from its amino acid sequence.
As POMT1 and POMT2 are known to precede POMGnT1 
in the α-DG O-mannosyl glycosylation pathway, by adding 
to serine/threonine residues the O-mannose unit serving as a 
substrate for POMGnT1 enzyme activity, we sought to inves-
tigate whether the genes encoding those two proteins were 
also expressed in the mammalian retina. As was the case for 
POMGnT1, we found that the POMT1 and POMT2 genes 
were expressed at the mRNA level in the neural retina of all 
mammals studied, as well as in the 661W photoreceptor cell 
line (Figure 1A). In keeping with these results, their encoded 
protein products, POMT1 and POMT2, were found to be 
present as well in the retinas of all mammals enlisted above 
and in the 661W cells (Figure 1B). Molecular masses for these 
proteins were, as expected, 82 and 84–85 kDa (depending on 
the species), respectively.
The intracellular localization of POMGnT1 in retinal 
cells is unknown. To investigate whether its distribution was 
cytoplasmic or nuclear or both, these protein fractions were 
extracted from the adult mouse retina and the 661W cells. As 
shown in Figure 1C, immunoblotting analysis revealed that 
POMGnT1 was distributed in the retina exclusively in the 
cytoplasm, whereas in the 661W photoreceptors this enzyme 
was found in the cytoplasmic and nuclear fractions. By using 
specific antibodies against β-tubulin III (an exclusively-
cytoplasmic protein) and lamin A/C (an exclusively-nuclear 
protein), we ascertained that the procedure we followed did 
not give cross contamination between the two fractions 
(Figure 1C).
Next, we set out to determine the distribution profile of 
POMGnT1 in retinal tissue. With this purpose, we performed 
immunofluorescence confocal microscopy analysis on retinal 
sections from adult mice. As shown, POMGnT1 localization 
Molecular Vision 2016; 22:658-673 <http://www.molvis.org/molvis/v22/658> © 2016 Molecular Vision 
663
Figure 1. Expression of POMGNT1, 
POMT1, and POMT2 at the mRNA 
and protein levels in the mamma-
lian retina and in the 661W cell line 
of cone photoreceptors. A: Total 
RNA was extracted from the neural 
retina of the species indicated and 
the 661W cell line. Expression 
of mRNAs encoded by the three 
genes was assessed with reverse 
transcription (RT)–PCR using 
specific primers. B: Immunoblot-
ting analysis of the expression of 
POMGnT1, POMT1, and POMT2 
on total protein extracts from the 
neural retina of the species listed 
and the 661W cell line. C: Total (T), 
cytoplasmic (C), and nuclear (N) 
protein fractions from the mouse 
neural retina and 661W cells were 
obtained, and immunoblotting 
was performed using antibodies to 
POMGnT1, β-tubulin III (a control 
cytoplasmic protein), and lamin 
A/C (two control, related nuclear 
proteins). The molecular sizes 
of the DNA (A) or protein (B, C) 
bands obtained are indicated to the 
right of each panel.
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was observed only in the photoreceptor IS layer (Figure 
2A,E), where immunoreactivity concentrated in a punctate 
band immediately above the photoreceptor nuclei stained 
with DAPI in the outer nuclear layer (Figure 2B). The signal 
from the retinal vessels was non-specific, as it persisted when 
the primary antibody was omitted (Figure 2C). Immunos-
taining with an antibody specific to cone arrestin revealed 
that POMGnT1 was located in the myoid region (Figure 2D), 
the photoreceptor IS portion where the endoplasmic reticulum 
and the Golgi complex are contained. To discern between 
these organelles, double immunostaining was performed by 
using antibodies to POMGnT1 together with an antibody 
against GM130 (Figure 2F), a structural protein of the 
Golgi apparatus widely used as a marker for this organelle. 
Significant colocalization of the immunolabeling was found 
all along the IS layer (Figure 2G,H, yellow; PC = 0.69±0.04). 
Localization of the Golgi complex in the myoid of the cone 
photoreceptors is illustrated in Figure 2I.
POMGNT1 was expressed in the photoreceptor cell line 
661W (Figure 1A,B) and the protein product distributed 
between the nucleus and the cytoplasm (Figure 1C). To 
further assess the intracellular localization of POMGNT1, 
cells were immunostained with anti-POMGnT1 antibodies 
and visualized with fluorescence microscopy. In keeping with 
immunoblotting data, it was also found that POMGnT1 was 
present in both cellular compartments (Figure 3A). A higher 
immunoreactivity density was found for POMGnT1 inside the 
nucleus, in the form of a punctate pattern, although without 
colocalization with DAPI-stained DNA in this compartment 
(Figure 3B,C,H; PC = 0.35±0.04). Immunolabeling in the 
cytoplasm and the nucleus was lost when the primary anti-
body was omitted (Figure 3D). In the cytoplasm, this enzyme 
Figure 2. Immunolocalization of POMGnT1 in the mouse neural retina. Double immunolabeling of mouse retinal sections for POMGnT1 
(A, B, D, E, G; red), cone arrestin (cArr; D, I; green), or the specific Golgi marker, GM130 (F, G, green; I, red) was performed. POMGnT1 
appeared immunoreactive in the IS layer of photoreceptors (A, E; asterisk). Nuclei stained with 4’,6-diamidino-2-phenylindole (DAPI) are 
displayed in blue (B–D, I). C: A negative control without a primary antibody did not show any signal in the IS layer. D: POMGnT1 was 
localized in the myoid portion of cones, where its immunostaining superimposes on cArr labeling (arrow). A portion of the IS layer from 
G is magnified in H, where POMGnT1 is shown to colocalize with GM130 within the myoid portion (yellow), where labeling of the latter 
is superimposed on cArr immunoreactivity (I; arrow). POMGnT1 red puncta in the IS in D and I not overlapped with cArr are presumed 
to belong to rod photoreceptors. Arrowheads point to non-specific immunostaining of retinal vessels with secondary antibodies to mouse 
immunoglobulin G in A, C, E. IS = inner segments; ONL = outer nuclear layer; OPL = outer plexiform layer; INL = inner nuclear layer; 
IPL = inner plexiform layer; GCL = ganglion cell layer; OS = outer segments, m = myoid; n = nucleus. Each bar equals 20 μm, except in 
D, H, and I: 5 μm.
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was found to distribute in dense, highly immunoreactive 
elements clustered at one pole of each nucleus stained with 
DAPI (Figure 3C,H), a location that was compatible with 
that of the Golgi complex. To investigate this possibility, we 
performed double immunolabeling for POMGnT1 (Figure 
3A) and the Golgi-resident protein, GM130 (Figure 3E). It 
was found that in the cytoplasm POMGnT1 was located in the 
Golgi complex of cultured photoreceptors, given the signifi-
cant colocalization found between the immunolabeling for 
these two proteins in this organelle (Figure 3F-H, yellow; PC 
= 0.70±0.06).
The concentration of the POMGnT1 enzyme found 
in the nucleus of 661W cells was somewhat surprising. To 
investigate the possible role of this protein in the nuclear 
compartment, we assessed whether, in addition to POMGnT1, 
other proteins of the α-DG O-glycosylation pathway were 
also located in the nucleus of these cells. We performed 
double immunolabeling using antibodies to POMGnT1 
in combination with specific antibodies against proteins 
POMT1 (Figure 4A) and POMT2 (Figure 4B). We observed 
that POMT1 and POMT2, similar to POMGnT1, showed a 
pattern of cytoplasmic plus nuclear distribution, although 
both were predominantly nuclear (Figure 4A,B). Although the 
two proteins were dispersed throughout the cytoplasm, they 
were found to highly colocalize inside the nucleus (Figure 
4C, yellow; PC = 0.88±0.03;). Double immunostaining for 
POMGnT1 and POMT1 revealed, however, that these two 
enzymes also colocalized inside the nucleus (Figure 4D,E; 
PC = 0.71±0.04). In the same fashion, significant colocaliza-
tion between POMGnT1 and POMT2 was observed upon 
double immunolabeling of 661W cells for these two enzymes 
(Figure 4G,H; PC = 0.74±0.04). The POMGnT1 colocaliza-
tion with POMT1 or POMT2 in the nucleus, however, was 
less than that of POMT1 with POMT2 (compare PC values). 
In contrast, no colocalization was essentially found between 
any of these three glycosyltransferases and the DAPI-stained 
regions (Figure 3B,C, Figure 4F,I; PC = 0.35±0.04, 0.46±0.03, 
and 0.46±0.03 for POMGnT1, POMT1, and POMT2, respec-
tively), the latter mainly corresponding to heterochromatin 
clusters inside the nuclei of the 661W photoreceptors.
Finally, to further analyze the intranuclear location in 
661W cells of the three enzymes, we performed a series of 
immunofluorescence microscopy studies in which antibodies 
against POMGnT1 (Figure 5A), POMT1 (Figure 5D), and 
POMT2 (Figure 5G) were used separately in combination 
with specific antibodies to the euchromatin marker histone 
Figure 3. Immunolocalization of POMGnT1 in the 661W photoreceptors. Cells were doubly immunolabeled with antibodies specific to 
POMGnT1 (A, green) and to the Golgi marker GM130 (E, red). 4’,6-Diamidino-2-phenylindole (DAPI)-stained nuclei are shown in blue (B, 
C, D, H). D: A negative control without a primary antibody to POMGnT1 did not show any signal. F: POMGnT1 immunoreactivity was 
distributed between the nucleus and the cytoplasm in 661W cells and colocalized with GM130 in the cytoplasm (yellow). Magnified views 
in C, G and H correspond to boxed areas in B and F. Each bar equals 20 μm, except in C, G, and H: 5 μm.
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H3 trimethylated on Lys-4 (H3K4me3). This analysis revealed 
that whereas POMGnT1 did not essentially colocalize with 
the euchromatin marker (Figure 5B,C; PC = 0.46±0.04), 
POMT1 was found to be located in the euchromatic regions of 
the 661W cell nucleus (Figure 5E,F, yellow; PC = 0.88±0.02). 
In the same fashion, POMT2 significantly immunolocalized 
to euchromatin in the 661W cells (Figure 5H,I, yellow; PC 
= 0.76±0.04). However, the essential absence of POMGnT1, 
POMT1, and POMT2 from heterochromatic areas, as deter-
mined by their lack of colocalization with DAPI-stained 
intranuclear clusters, was corroborated for POMGnT1 and 
POMT1 by their failure to colocalize with the heterochro-
matin marker, HP1α (data not shown).
DISCUSSION
Dystroglycanopathies are a group of inherited neuromus-
cular dystrophies that affect the muscle, CNS, and eye, 
whose underlying basis is a deficient glycosylation of α-DG 
[3,4,6-9]. The first gene identified as related to this type of 
diseases was POMGNT1, as causative of MEB [14-17], and 
later on also of WWS and other, less severe dystroglycanopa-
thies [15,16,18,19,21,41]. Mutations in the gene encoding the 
POMT1 enzyme were shortly thereafter found to be associ-
ated mainly with WWS [42], followed by POMT2 [43]. In 
patients with MEB, the molecular weight of α-DG decreases 
by approximately 60 kDa in skeletal muscle and the brain, 
which is attributable to α-DG hypoglycosylation derived from 
loss of function of POMGnT1 [44,45]. Patients with MEB 
display a variety of ocular abnormalities, including elec-
troretinographic (ERG) changes, retinal dysplasia, myopia, 
glaucoma, microphthalmia, cataracts, retinal degeneration, 
detachment, and abnormal vascularization, among many 
others (OMIM 253280) [46-49]. To date, two Pomgnt1 
knockout (KO) gene mouse models have been generated, the 
first by retroviral insertion of a gene-trapping cassette into 
the gene's 5′ untranslated region (UTR) [28], and the second 
by targeted replacement of a gene fragment containing exon 
18 by a neo cassette [29]. Both mice models were found to 
Figure 4. Immunolocalization of 
POMGnT1 and protein O-manno-
sylt ransferases POMT1 and 
POMT2 in 661W photoreceptors. 
Cells were immunostained with 
antibodies specific for POMT1 
(A, green) and POMT2 (B, red). 
These two proteins colocalized 
nearly completely in the nuclei of 
the 661W cells (C, yellow). Double 
immunostaining with antibodies 
specific for POMGnT1 (green) and 
POMT1 (red) is shown in D and for 
POMGnT1 (green) and POMT2 
(red) in G. Magnified views in E 
and H correspond to boxed areas 
in D and G, respectively, addition-
ally stained with 4’,6-diamidino-
2-phenylindole (DAPI) in blue in 
F and I. Significant colocalization 
between POMGnT1 and POMT1 
(E, F) and between POMGnT1 and 
POMT2 (H, I) is observed. Each 
bar equals 20 μm, except in E, F, 
H, and I: 10 μm.
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develop multiple defects in muscle, brain, and eye, mimicking 
those exhibited by people affected by dystroglycanopathies 
[28-30,50,51]. Ocular alterations observed in patients with 
MEB or WWS and in these mouse models underline the 
relevance of analyzing the distribution of POMGnT1 in 
the mammalian retina in general, and in photoreceptors in 
particular, to obtain useful information about POMGnT1 
function in retinal cells.
In this work, we detected expression of the POMGNT1 
gene at the mRNA and protein levels in all mammalian 
species studied, including rodents (mouse and rat), bovine, 
and primates (monkey and humans). The gene’s encoded 
mRNA transcript and POMGnT1 protein product were also 
detected in an established photoreceptor cell line, 661W, 
a mouse retinal transformed cell line with cone proper-
ties. In all cases, POMGnT1 showed a molecular mass on 
immunoblots in agreement with that predicted from its 
amino acid sequence (75 kDa) and with previous studies. In 
this context, POMGnT1 has been previously detected with 
immunoblotting only in the muscle of patients with MEB 
and healthy individuals, where the protein’s molecular mass 
remained unchanged [52]. Other than this, human POMGnT1 
has been detected only as exogenously overexpressed, with 
immunoblotting in transfected COS-7 cells [21] and with 
immunocytochemistry in transfected COS-7 and C2C12 cell 
lines [25,26]. Therefore, our work represents the first instance 
in which endogenous expression of POMGnT1 is reported 
in a nervous tissue, the retina, and in a non-transfected cell 
line, 661W.
The glycosylation of α-DG is a post-translational modi-
fication that takes place in the endoplasmic reticulum and 
the Golgi apparatus. Therefore, as POMGnT1 is involved 
in the biosynthetic (branched) pathway of two of the three 
known α-DG O-mannosyl glycan core structures, M1 and 
M2 (but not M3) [8,9,11], the immunolocalization of this 
protein in the Golgi apparatus in retinal cells is in agree-
ment with the protein’s proposed function in mammalian 
tissues. The presence of this protein in the Golgi complex 
Figure 5. Intranuclear immunolo-
calization of POMGnT1 together 
with POMT1 and POMT2 in 
euchromatin regions of the 661W 
photoreceptors. Cells were doubly 
immunostained for POMGnT1 
(A, green), POMT1 (D, green), or 
POMT2 (G, green) and the euchro-
matin marker H3K4me3 (B, E, H; 
red). Essentially, no colocalization 
was found between POMGnT1 and 
euchromatin (B, C). In contrast, 
extensive colocalization was found 
between POMT1 and euchromatin 
(E, F; yellow), and between POMT2 
and euchromatin (H, I; yellow). 
Enlarged micrographs in C, F and 
I correspond to the boxed areas in 
panels B, E and H, respectively. 
Each bar equals 20 μm, except in 
C, F, and I: 10 μm.
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had also been observed when exogenously expressed from 
the human POMGNT1 gene in transfected C2C12 and COS-7 
cells, where POMGnT1 has been shown to colocalize in the 
Golgi complex and interact with fukutin [25,26], the product 
of the FKTN gene (Gene ID 2218, OMIM 607440) associ-
ated with Fukuyama congenital muscle dystrophy, and other 
dystroglycanopathies. Recently, by cotransfection of the 
POMGNT1 gene with that encoding human GOLPH3, it has 
been demonstrated that the latter mediates the Golgi local-
ization of POMGnT1 in HeLa cells by physically interacting 
with its cytoplasmic tail, thus targeting and maintaining 
the enzyme in this organelle [27]. Here, we have shown 
for the first time the presence of POMGnT1 in the Golgi 
complex in an adult mammalian tissue, namely, the retina. 
Specifically, we located POMGnT1 in the myoid region of 
the inner segments of photoreceptors, the place where the 
protein biosynthetic machinery is concentrated in this cell 
type, including ribosomes, the endoplasmic reticulum and the 
Golgi complex [53]. The location of POMGnT1 in the Golgi 
complex was conserved in the transformed photoreceptor 
cell line, 661W. These results support that the function of 
POMGnT1 in retinal photoreceptors, as established in other 
cell types and tissues, is to catalyze the second step in the 
O-mannosyl glycosylation of α-DG, that is, the addition of 
N-acetylglucosamine units onto O-mannose, previously 
added by virtue of POMT1 and POMT2 action in the endo-
plasmic reticulum. It cannot be ruled out at present that other 
O-mannosylated proteins could serve as well as POMGnT1 
substrates remaining to be identified in this tissue.
In the mammalian retina, α-DG has been localized in 
the outer plexiform layer (OPL), the endothelium of blood 
vessels, and the inner limiting membrane (ILM) [50,54-56]. 
In the retina of Pomgnt1 KO mice, thinning of the outer and 
inner nuclear layers (ONL and INL, respectively) has been 
described that was accompanied by absent or residual α-DG 
glycosylation and pikachurin immunoreactivity in the OPL 
[50,57,58]. At the physiologic level, a reduction in the ampli-
tude and a delay in implicit time has been found for the ERG 
a- and b-waves [28,50]. In addition, a disruption of the ILM 
has been reported together with increased reactivity of astro-
cytes and Müller glia [30,50]. Our results are thus supportive 
that POMGnT1 performs a fundamental role in photorecep-
tors, that is, the glycosylation of α-DG at the Golgi apparatus, 
which is required for its interaction with its ligand at the OPL 
extracellular matrix, pikachurin [57,58]. This binding, in 
turn, has proven to be crucial for the structure and function 
of synapses established between photoreceptors and their 
postsynaptic cells [13,59]. The phenotypic and physiologic 
abnormalities observed in Pomgnt1 KO mice thus indicate a 
significant dysfunction originating from hypoglycosylation 
of α-DG in photoreceptors and affecting other layers of the 
retina [28,50].
To date, POMGnT1 has not been detected in the nucleus 
of any vertebrate tissue or cell line. However, our results 
obtained with immunoblotting have shown the presence 
of this protein in the nuclear fraction of the 661W photore-
ceptors, and immunocytochemical studies have revealed a 
concentration of this protein in the nuclear compartment. The 
formal possibility exists that POMGnT1 is (mis)localized to 
this organelle due to their lack of normal cell polarity, this 
derived from their absence of interaction with RPE cells. This 
has been used to explain the distribution of cone opsins all 
over the cell, including the nucleus, in 661W photoreceptors 
given their lack of outer segments [34]. Although we cannot 
rule out this possibility, POMGnT1 is not the first instance 
of a protein involved in the glycosylation of α-DG being 
detected inside the nucleus, since fukutin has been localized 
to this compartment in addition to the endoplasmic reticulum 
and the Golgi complex in two human cancer cell lines, HeLa 
(cervical cancer) and ZR-75-1 (mammary tumor) [60]. As in 
these cell lines α-DG is not detected in the nucleus, a new 
function has been proposed for fukutin in this compartment 
other than involvement in glycosylation of α-DG, such as the 
suppression of cell proliferation [60]. In contrast, β-DG, but 
not α-DG, has been detected in the nucleus of breast [61] and 
prostate cancer (tissue and cell lines) [62,63], as well as in 
several well-known, established cell lines of many different 
tissue and organ origins, such as C2C12 mouse myoblasts 
[64], PC12 rat pheochromocytoma [65], A549 (lung cancer), 
Hepa-1 (mouse liver), and even HeLa cells [66]. In several 
of these cell lines, (unglycosylated) β-DG has been found to 
form part, as an inner nuclear membrane protein, of a nuclear 
complex with dystrophin (Dp71 isoform), α-sarcoglycan, 
α-dystrobrevin, and α-syntrophin, devoid of α-DG and whose 
proposed function would be to act as a nuclear scaffolding 
complex [67-69].
We have made our best attempt to detect in the nuclei 
of 661W photoreceptors β-DG, as well as α-DG, either 
glycosylated or unglycosylated (core α-DG), with negative 
results (data not shown). However, we observed β-DG and 
glycosylated α-DG in the cytoplasm of these cells, by using 
conventional antibodies widely used by many authors (data 
not shown). We then tried to localize in 661W cells other 
proteins involved in α-DG glycosylation, such as POMT1 and 
POMT2, which is responsible for catalyzing the preceding 
step of this pathway [22,23]. These two proteins were found, 
in addition to the cytoplasm (where they would carry out 
α-DG O-mannosylation) in the nuclei of 661W cells, where 
they colocalized with the POMGnT1 enzyme. Interestingly, 
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POMT1 and POMT2 colocalized nearly completely with each 
other, which speaks in favor of these two proteins forming a 
heterodimer required for their protein O-mannosyltransferase 
activity [22,23] and highly colocalized with the euchro-
matic—but not heterochromatic—regions within the nucleus 
of 661W cells. To our knowledge, this is the first instance 
of dystroglycanopathy-related proteins being associated with 
chromatin and perhaps exerting an indirect transcriptional 
regulatory role, distinct from their function in α-DG glyco-
sylation in the cytoplasm.
As a difference compared to photoreceptors in their 
natural context of the retina, 661W is a cell line derived from 
a retinal tumor, which have undergone transformation as a 
consequence of expressing the SV40 T viral oncoprotein, and 
thus exhibit an unlimited capacity of cell division [33]. An 
increasing number of studies have unveiled that many tumor 
tissues and cell lines, including prostate, digestive system, 
renal cancer, and glioblastomas, exhibit a downregulation of 
α-DG and β-DG protein levels [70-73] or a hypoglycosylation 
of α-DG[73-78]. Recently, POMGnT1 levels have been found 
altered in human glioblastomas in a correlated fashion with 
their tumor grade (malignancy) [79]. This ample set of results 
strongly point to a role of DG levels of expression or glycosyl-
ation (or both) in modulation of cellular proliferation. In this 
context, a picture has emerged in recent years in which tumor 
progression involves downregulation of dystroglycanopathy-
related genes, this contributing to their detachment from the 
extracellular matrix and acquisition of migratory properties. 
This is the case of LARGE (Gene ID 9215, OMIM 603590); 
LARGE2 (Gene ID 120071, OMIM 609709); B3GNT1 (Gene 
ID 11041, OMIM 605517), and ISPD (Gene ID 729920, 
OMIM 614631) in prostate cancer [73,75,80], tongue cancer 
[74], or renal carcinoma [76].
Given that DG appears to be absent from the nucleus 
of 661W cells, the possibility can be raised that POMGnT1 
could be involved, possibly in cooperation with the POMT1/2 
heterodimer, in the glycosylation of yet-to-be identified 
nuclear proteins perhaps with a modulatory role of cell adhe-
sion/migration or proliferation abilities. Recently, a new set 
of proteins have been found to be O-mannosyl glycosylated 
in the mouse brain in a POMGnT1-dependent fashion [81]. 
These proteins encompass mainly cadherins and plexins, 
although not any known transcription factor. However, a 
protein-tyrosine-phosphatase named RPTPζ/phosphacan has 
recently emerged as an apparent new substrate for POMGnT1 
[82]. It is therefore tempting to speculate that POMGnT1 
could indirectly influence these cellular properties by modu-
lating intranuclear signal transduction. Further research is 
needed to clarify the role of POMGnT1 in the nucleus of 
dividing photoreceptors, where this protein is not found in 
its natural retinal environment.
APPENDIX 1.
STR analysis. To access these data, click or select the words 
"Appendix 1".
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